Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetone SCHEMBL29032239 | 0.96 | TSHR (0.47) | TSHRLMNAALDH1A1TDP1TP53 | |
| Acetone SCHEMBL2748125 | 0.96 | TSHR (0.47) | TSHRLMNAALDH1A1TDP1TP53 | |
| Acetone SCHEMBL28124568 | 0.96 | TSHR (0.47) | TSHRLMNAALDH1A1TDP1TP53 | |
| Acetic Acid SCHEMBL8834547 | 0.93 | FFAR3 (0.47) | TSHRLMNAALDH1A1TDP1TP53 | |
| Acetone SCHEMBL11747870 | 0.93 | TSHR (0.45) | TSHRLMNAALDH1A1TDP1TP53 | |
| Acetic Acid SCHEMBL87553 | 0.89 | FFAR3 (0.50) | TSHRLMNAALDH1A1TDP1TP53 | |
| Acetic Acid SCHEMBL27469271 | 0.89 | FFAR3 (0.50) | TSHRLMNAALDH1A1TDP1TP53 | |
| Acetone SCHEMBL11413386 | 0.87 | TSHR (0.41) | TSHRLMNAALDH1A1TDP1BLM | |
| Acetic Acid SCHEMBL8835007 | 0.86 | FFAR3 (0.47) | TSHRLMNAALDH1A1TDP1TP53 | |
| Acetamide SCHEMBL27400127 | 0.86 | LMNA (0.53) | TSHRLMNAALDH1A1TDP1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107602546-B | Crystal form of compound, preparation method, composition and application thereof | 武汉朗来科技发展有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-113929661-A | Dabigatran etexilate intermediate and preparation method thereof | 石药集团恩必普药业有限公司 | 2022-01-14 | — | — | CN | claimed |
| CN-109438514-B | Preparation method of adefovir dipivoxil | 湖南方盛制药股份有限公司 | 2020-12-18 | — | — | CN | claimed |
| US-10646832-B2 | High selectivity copolyimide membranes for separations | UOP LLC | 2020-05-12 | — | — | US | claimed |
| EP-3348546-B1 | CRYSTALLINE FORM OF ANDROGEN RECEPTOR INHIBITOR AND PREPARATION METHOD THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2020-04-29 | — | — | EP | claimed |
| EP-3348546-A1 | CRYSTALLINE FORM OF ANDROGEN RECEPTOR INHIBITOR AND PREPARATION METHOD THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2018-07-18 | — | — | EP | claimed |
| US-20180050309-A1 | HIGH SELECTIVITY COPOLYIMIDE MEMBRANES FOR SEPARATIONS | UOP LLC | 2018-02-22 | — | — | US | claimed |
| CN-107602546-A | Crystal formation of compound and preparation method thereof, composition and application | 武汉朗来科技发展有限公司 | 2018-01-19 | — | — | CN | claimed |
| CN-107001284-A | A kind of crystal form of androgen receptor inhibitor and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2017-08-01 | — | — | CN | claimed |
| US-9669363-B2 | High permeance membranes for gas separations | UOP LLC (US) | 2017-06-06 | — | — | US | claimed |
| US-20080200668-A1 | Industrial Process for the Preparation of 17-Hydroxy-6Beta, 7Beta; 15Beta, 16Beta-Bismethylene-3-Oxo-17Alpha-Pregn-4-Ene-21-Carboxylic Acid Y-Lactone and Key Intermediates for this Process | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-08-21 | — | — | US | claimed |
| US-20080194812-A1 | Process for the Preparation of 17-Hydroxy-6Beta, 7Beta; 15Beta, 16Beta-Bismethylene- 17Alpha-Pregn-4-Ene-3-One-21-Carboxylic Acid Y-Lactone and Key Intermediates for this Process | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-08-14 | — | — | US | claimed |
| US-20080142440-A1 | Liquid Separations Using High Performance Mixed Matrix Membranes | UOP LLC | 2008-06-19 | — | — | US | claimed |
| CN-101061132-A | Process for the preparation of 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta-dimethylene-17 alpha-pregn-4-en-3-one-21-carboxylic acid gamma-lactone and key intermediates used in the process | RICHTER GEDEON VEGYZETI GYAR R (HU) | 2007-10-24 | — | — | CN | claimed |
| CN-101061133-A | Industrial process for the preparation of 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta-dimethylene-3-oxo-17 alpha pregn-4-ene-21-carboxylic acid gamma-lactone and key intermediates used in the process | RICHTER GEDEON VEGYZETI GYAR R (HU) | 2007-10-24 | — | — | CN | claimed |
| EP-1817326-A1 | INDUSTRIAL PROCESS FOR THE PREPERATION OF 17-HYDROXY -6 BETA, 7-BETA, 15-BETA, 16-BETA-BISMETHYLENE-3-OXO 17-ALPHA PREGN-4-ENE-21-CARBOXYLIC ACID GAMMA-LACTONE AND KEY INTERMEDIATES FOR THIS PROCESS | Richter Gedeon Vegy Szeti Gy R Rt. (HU) | 2007-08-15 | — | — | EP | claimed |
| WO-2006059167-A1 | INDUSTRIAL PROCESS FOR THE PREPARATION OF 17-HYDROXY-6β,7β;15β,16β-BISMETHYLENE-3-OXO-17α-PREGN-4-ENE-21-CARBOXYLIC ACID Ϝ-LACTONE AND KEY-INTERMEDIATES FOR THIS PROCESS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2006-06-08 | — | — | WO | claimed |
| CN-1183151-C | Spherical telithromycikn clusters, method for the production and use thereof in the preparation of pharmaceutical forms | ���ĵ�˹ҩƷ��˾ | 2005-01-05 | — | — | CN | claimed |
| EP-1212336-B1 | METHOD FOR THE PRODUCTION AND USE OF SPHERICAL TELITHROMYCIN CLUSTERS IN THE PREPARATION OF PHARMACEUTICAL FORMS | AVENTIS PHARMA SA (FR) | 2003-12-03 | — | — | EP | claimed |
| CN-1371386-A | Spherical telithromycikn clusters, method for the production and use thereof in the preparation of pharmaceutical forms | AVENTIS PHARMA SA (FR) | 2002-09-25 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200668-A1 | Industrial Process for the Preparation of 17-Hydroxy-6Beta, 7Beta; 15Beta, 16Beta-Bismethylene-3-Oxo-17Alpha-Pregn-4-Ene-21-Carboxylic Acid Y-Lactone and Key Intermediates for this Process | HSD17B7, CYP17A1, HSD17B11 | TSHR 2195/4885LMNA 2502/4885ALDH1A1 661/4885 |
| US-20080194812-A1 | Process for the Preparation of 17-Hydroxy-6Beta, 7Beta; 15Beta, 16Beta-Bismethylene- 17Alpha-Pregn-4-Ene-3-One-21-Carboxylic Acid Y-Lactone and Key Intermediates for this Process | CYP17A1, HSD17B7, HSD17B11 | TSHR 2431/4885LMNA 1403/4885ALDH1A1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.